[go: up one dir, main page]

WO1999018120A1 - Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs - Google Patents

Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs Download PDF

Info

Publication number
WO1999018120A1
WO1999018120A1 PCT/IB1998/001693 IB9801693W WO9918120A1 WO 1999018120 A1 WO1999018120 A1 WO 1999018120A1 IB 9801693 W IB9801693 W IB 9801693W WO 9918120 A1 WO9918120 A1 WO 9918120A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclosporine
meleu
complex
derivative
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/001693
Other languages
English (en)
Inventor
S. Selvaraj Naicker
Randall W. Yatscoff
Robert T. Foster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isotechnika Inc
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU94542/98A priority Critical patent/AU750245B2/en
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Priority to BR9811716-5A priority patent/BR9811716A/pt
Priority to CA002298572A priority patent/CA2298572C/fr
Priority to AT98947718T priority patent/ATE314388T1/de
Priority to NZ502362A priority patent/NZ502362A/en
Priority to EP98947718A priority patent/EP0991660B8/fr
Priority to KR1020007003743A priority patent/KR100585348B1/ko
Priority to HK00105620.7A priority patent/HK1026432B/en
Priority to JP2000514928A priority patent/JP4261049B2/ja
Priority to DE69832984T priority patent/DE69832984T2/de
Publication of WO1999018120A1 publication Critical patent/WO1999018120A1/fr
Priority to NO20001020A priority patent/NO324042B1/no
Anticipated expiration legal-status Critical
Priority to US09/634,945 priority patent/US6613739B1/en
Priority to US09/639,708 priority patent/US6605593B1/en
Priority to AU27567/02A priority patent/AU774744B2/en
Priority to AU2004218637A priority patent/AU2004218637B2/en
Priority to US11/105,897 priority patent/US7358229B2/en
Priority to US11/245,775 priority patent/US7538189B2/en
Priority to US11/280,666 priority patent/US7521421B2/en
Priority to US12/427,692 priority patent/US20090318336A1/en
Priority to US13/048,258 priority patent/US20110166080A1/en
Priority to US13/402,370 priority patent/US20120214745A1/en
Priority to US14/182,231 priority patent/US20140235819A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Definitions

  • Cyclosporin derivatives of the present invention are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives.
  • the cyclosporin derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by:
  • the cyclosporins are a family of, neutral, hydrophobic cyclic undecapeptides, containing a novel nine-carbon amino acid (MeBmt) at position 1 of the ring that exhibit potent immunosuppressive, antiparasitic, fungicidal, and chronic anti-inflammatory properties.
  • the naturally occurring members of this family of structurally related compounds are produced by various fungi imperfecti.
  • Cyclosporines A and C are the major components. Cyclosporine A, which is discussed further below, is a particularly important member of the cyclosporin family of compounds. Twenty four minor metabolites, also oligopeptides, have been identified: Lawen et al, J. Antibiotics 42, 1283 (1989); Traber et al, Helv. Chim. Acta 70, 13 (1987); Von Wartburg and Traber Prog. Med. Chem., 25, 1 (1988).
  • Cyclosporin was discovered to be immunosuppressive when it was observed to suppress antibody production in mice during the screening of fungal extracts. Specifically, its suppressive effects appear to be related to the inhibition of T-cell receptor-mediated activation events. It accomplishes this by interrupting calcium dependent signal transduction during T-cell activation by inactivating calmodulin and cyclophilin, a peptidly propyl isomerase. It also inhibits lymphokine production by T-helper cells in vitro and arrests the development of mature CD8 and CD4 cells in the thymus.
  • T-lymphocytes include inhibition of IL-2 producing T-lymphocytes and cytotoxic T-lymphocytes, inhibition of IL-2 released by activated T-cells, inhibition of resting T-lymphocytes in response to alloantigen and exogenous lymphokine, inhibition of IL-1 production, and inhibition of mitogen activation of IL-2 producing T-lymphocytes. Further evidence indicates that the above effects involve the T-lymphocytes at the activation and maturation stages.
  • TCR T cell receptor
  • MHC major histocompatibility
  • TCR signal transmission pathway exact method of transmission unknown
  • NF-AT nuclear factors of activated T-cells
  • IL-2 lymphokine interleukin-2
  • T-cell activation also involves the appearance of the lymphokine receptor IL-2R on the cell srface.
  • IL-2 binds to IL-2R
  • a lymphokine receptor (LKR) signal transmission pathway is activated.
  • the immunosuppressive drug, rapamycin inhibits this pathway.
  • CsA is a potent inhibitor of TCR-mediated signal transduction pathway. It inhibits binding of NF-AT to the IL-2 enhancer, and thus inhibits transcriptional activation.
  • CsA binds to cyclophilin, which binds to calcineurin, which is a key enzyme in the T-cell signal transduction cascade.
  • Cyclophilin is found in prokaryotic and eukarotic organisms and is ubiquitous and abundant. Cyclophilin is a single polypeptide chain with 165 amino acid residues. It has a molecular mass of 17.8 kD. A roughly spherical molecule with a radius of 17 angstroms, cyclophilin has a eight-stranded antiparallel beta barrel. Inside the barrel, the tightly packed core contains mostly hydrophobic side chains. CsA has numerous hydrophobic side chains which allow it to fit into the cyclophilin beta barrel. Cyclophillin catalyzes the interconversion of the cis and trans-rotamers of the peGIFdyl-prolyl amide bond of peptide and protein substrates.
  • Cyclophilin is identical in structure with peptidyl prolyl cis-trans isomerase and bears structural resemblance to the superfamily of proteins that transports ligands such as retinol-binding protein (RBP). These proteins carry the ligand in the barrel core. But cyclophilin actually carries the ligand binding site on the outside of the barrel. The tetrapeptide ligand binds in a long deep groove on the protein surface between one face of the beta barrel and the Thrl 16-Glyl30 loop.
  • CsA as discussed above, binds to the cyclophilin beta barrel.
  • CyP A residues define the CsA binding site. These residues are Arg 55, Phe 60, Met 61, Gin 63, Gly 72, Ala 101, Asn 102, Ala 103, Gin
  • Residues 4, 5, 6, 7, 8 of CsA protrude out into the solvent and are thought to be involved in binding the effector protein, calcineurin (Pflugl, G., Kallen, J., Schirmer, T., Jansonius, J.N., Zurini, M.G.M., &
  • the CsA-CyP A complex inhibits the phosphatase activity of the heterodimeric protein serine/ threonine phosphatase or calcineurin (Liu, J., Farmer, J.D., Lane, W.S., Friedman, J., Weissman, I., &
  • CyP A binds CsA with an affinity of ca. 10 nM.
  • the complex is then presented to calcineurin (Liu, J., Farmer, J.D., Lane, W.S., Friedman, J., Weissman, I., & Schreiber, S.L. (1991) Cell 66, 807-15.).
  • Calcineurin dephosphorylates the transcription factor NFAT found in the cytoplasm of T-cells.
  • CsA-CyP A complex inhibits the phosphatase activity of calcineurin and ultimately immunosuppression (Etzkorn, F. A., Chang, Z., Stolz, L.A., &Walsh, C.T. (1994) Biochemistry 33, 2380-2388.). Neither CsA or CyP A alone are important immunologically.
  • Cyclosporine is metabolized in liver, small intestine and kidney to more than 30 metabolites.
  • the structure of 13 metabolites and 2 phase II metabolites have been identified and at least 23 further metabolites have been isolated by HPLC and their structures characterized by mass spectrometry.
  • the reactions involved in phase I metabolism of cyclosporine are hydroxylation, demethylation as well as oxidation and cyclisation at amino acid 1.
  • Several clinical studies and reports showed an association between blood concentrations of cyclosporine metabolites and neuro- or nephrotoxicity. In vitro experiments indicate that metabolites are considerably less immunosupressive and more toxic than CsA.
  • the cyclosporin family of compounds find utility in the prevention of rejection or organ and bone marrow transplants; and in the treatment of psoriasis, and a number of autoimmune disorders such as type 1 diabetes mellitus, multiple sclerosis, autoimmune uveitis, and rheumatoid arthritis. Additional indications are discussed infra.
  • Cyclosporin A is a cyclic peptide which contains several N-methyl amino acids and, at position-8, contains a D-alanine.
  • the structure of Cyclosporin A a is given below:
  • each of the amino acids of the disclosed cyclosporin is of the L-configuration.
  • cyclosporin C which differs from cyclosporin A by the threonine at position-2 may be identified as [Thr] 2 -cyclosporin or [Thr] 2 -CsA.
  • cyclosporin B is [Ala] 2 -CsA
  • cyclosporin D is [Val] 2 -CsA
  • cyclosporin E is [Val] "-CsA
  • cyclosporin F is [3- DesoxyMeBmtj'-CsA
  • cyclosporin G is [NVa] 2 -CsA
  • cyclosporin H is [D-MeVal] u -CsA.
  • D-Serine and D-Threonine have been introduced into the 8-position of cyclosporin A by biosynthesis resulting in active compounds. See R. Traber et al. J. Antibiotics 42, 591 (1989). D-Chloroalanine has also been introduced into position-8 of Cyclosporin A by biosynthesis. See A. Lawen et al J. Antibiotics 52, 1283 (1989).
  • Immunoregulatory abnormalities have been shown to exist in a wide variety of autoimmune and chronic inflammatory diseases, including systemic lupus erythematosis, chronic rheumatoid arthritis, type 1 diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis and other disorders such as Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, and Graves ophthalmopathy.
  • systemic lupus erythematosis chronic rheumatoid arthritis
  • type 1 diabetes mellitus inflammatory bowel disease
  • biliary cirrhosis uveitis
  • multiple sclerosis and other disorders such as Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, and
  • the host lymphocytes recognize the foreign tissue antigens and begin to produce antibodies which lead to graft rejection.
  • autoimmune or a rejection process tissue destruction caused by inflammatory cells and the mediators they release.
  • Anti-inflammatory agents such as NSAID's (Non-Steroidal Anti- inflammatory Drugs), and corticosteroids act principally by blocking the effect of, or secretion of, these mediators, but do nothing to modify the immunologic basis of the disease.
  • cytotoxic agents such as cyclophosphamide, act in such a nonspecific fashion that both the normal and autoimmune responses are shut off. Indeed, patients treated with such nonspecific immunosuppressive agents are as likely to succumb to infection as they are to their autoimmune disease.
  • a cyclosporin such as cyclosporine A
  • cyclosporine A is not cytotoxic nor myelotoxic. It does not inhibit migration of monocytes nor does it inhibit granulocytes and macrophage action. Its action is specific and leaves most established immune responses intact. However, it is nephrotoxic and is known to cause the following undesirable side effects: ( 1 ) abnormal liver function;
  • Cyclosporin Derivatives discloses cyclosporin D, dihydrocyclosporin D, and isocyclosporin D, and a process for producing same.
  • the present invention concerns chemically substituted and deuterated analogs of cyclosporine A and related cyclosporines.
  • An additional object of the present invention is to provide pharmaceutical compositions for administering to a patient in need of the treatment one or more of the active immunosuppressive agents of the present invention.
  • Still a further object of this invention is to provide a method of controlling graft rejection, autoimmune and chronic inflammatory diseases by administering a sufficient amount of one or more of the novel immunosuppressive agents in a mammalian species in need of such treatment.
  • it is the object of this invention to provide processes for the preparation of the active compounds of the present invention.
  • Substitution and deuteration of the cyclosporine molecule results in altered physicochemical and pharmacokinetic properties which enhance its usefulness in the treatment of transplantation rejection, host vs. graft disease, graft vs. host disease, aplastic anemia, focal and segmental glomerulosclerosis, myasthenia gravis, psoriatic arthritis, relapsing polychondritis and ulcerative colitis.
  • Embodiments of the invention include CsA derivatives wherein one or more hydrogen atoms in the 1 , 3 and 9 amino acid positions are substituted with a deuterium atom and wherein the cyclosporine A derivatives are optionally chemically substituted at the amino acid 9 position.
  • a further specific embodiment of the invention is the CsA derivative represented by formula I:
  • R is (i) a deuterium or (ii) a saturated or unsaturated straight or branched aliphatic chain of from 2 to 16 carbon atoms and containing one or more deuterium atoms or an ester, ketone or alcohol of the carbon chain and optionally containing one or more substituents selected from halogen, nitro, amino, amido, aromatic, and heterocyclic, or (iii) R is an aromatic or heterocyclic group optionally containing a deuterium atom, or (iv) R is a methyl group and X, Y, and Z are hydrogen or deuterium provided that at least one of X, Y or Z is deuterium and R' is an OH or an ester or is an O and together with a carbon adjacent to a double bond on amino acid 1 form a heterocyclic ring such as 5-membered rings where the heteroatom is oxygen.
  • Other specific embodiments of the present invention include the CsA derivative of formula I where R is a saturated or unsaturated carbon chain
  • Figure 1 is the structure of cyclosporine A showing a site of deuteration at the amino acid 3 position.
  • Figure 2 is the structure of cyclosporine A showing a site of deuteration at the amino acid 9 position.
  • FIG. 3 is scheme I of the synthesis of the cyclosporine derivatives.
  • Figure 4 is scheme II of the synthesis of the cyclosporine derivatives.
  • Figure 5 is a graph of the results of the calcineurin assay of Example 9.
  • Figure 6 is a graph of the results of a mixed lymphocyte reaction assay of Example 10.
  • Substitution of deuterium in methyl groups of cyclosporine will result in a slower rate of oxidation of the C-D bond relative to the rate of oxidation of a non-deuterium substituted C-H bond.
  • the isotopic effect acts to reduce formation of demethylated metabolites and thereby alters the pharmacokinetic parameters of the drug.
  • Lower rates of oxidation, metabolism and clearance result in greater and more sustained biological activity.
  • Deuteration is targeted at various sites of the cyclosporin molecule to increase the potency of drug, reduce toxicity of the drug, reduce the clearance of the pharmacologically active moiety and improve the stability of the molecule.
  • Stable isotopes are nonradioactive isotopes which contain one additional neutron than the normally abundant isotope of the respective atom.
  • Deuterated compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the non deuterated parent compound. (Blake et al. J. Pharm. Sci. 64, 3, 367-391,1975). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985).
  • Incorporation of a heavy atom particularly substitution of deuterium for hydrogen can give rise to an isotope effect that could alter the pharmacokinetics of the drug. This effect is usually insignificant if the label is placed at a metabolically inert position of the molecule.
  • Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These changes may influence the fate of the drug at different steps along its passage through the body.
  • Absorption, distribution, metabolism or excretion can be changed. Absorption and distribution are processes that depend primarily on the molecular size and the lipophilicity of the substance.
  • Drug metabolism can give rise to large isotopic effect if the breaking of a chemical bond to a deuterium atom is the rate limiting step in the process. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom.
  • reaction involving breaking a C-D bond can be up to 700 per cent slower than a similar reaction involving breaking a C-H bond. If the C-D bond is not involved in any of the steps leading to the metabolite , there may not be any effect to alter the behavior of the drug. If a deuterium is placed at a site involved in the metabolism of a drug .
  • the staring material for the preparation of the compounds of this invention is cyclosporine A.
  • the process for preparing the compounds of the present invention are illustrated as shown in scheme I in figure 3. It will be readily apparent to one of ordinary skill in the art reviewing the synthetic route depicted below that other compounds with formula I can be synthesized by substitution of appropriate reactants and agents in the synthesis shown below.
  • the first step in the process for making deuterated cyclosporin analogs is the preparation of the key intermediate 3_and 6 . This can be achieved by the oxidation of the double bond in the amino acid 1. Treatment of cyclosporin with acetic anhydride and excess of dimethylaminopyridine provided the hydroxyl protected acetyl cyclosporin.
  • the aldehyde compound 3 was further treated with various deuterated alkyl or aryl triphenyl phosphonium derivatives(wittig reagents) and hydrolysis by alkaline solution provided the final derivatives ( 5 a-h).
  • the aldehyde derivative 3 was treated with the Wittig reagent prepared by using standard procedure.
  • the resultant product on mild acid hydrolysis provided the key intermediate aldehyde product 6
  • This method provides control over the extension of the diene system. By using this approch, olefinic double bonds can be introduced step by step.
  • a third approach to prepare the deuterated compounds 5a-h- is by heating non deuterated cyclosporin analogs described earlier, in a deuerated solvent such as deuterated water, deuterated acetic acid in the presence of acid or base catalyst.
  • Preferred cyclosporins of the present invention are those which both contain a deuterium and a chemical substitution on amino acid 1 such as those of formula II:
  • Method B To a stirred solution of compound 3 (287mg, 0.23mmol) in THF (5mL) under Ar at -78°C was carefully added a solution of phosphorus ylid (formed by the addition of sodium hexamethyldisilylamide (1.0M; 2.25mL, 2.25mmol, ⁇ 10eq) to a suspension of ⁇ -ethyltriphenylphosphonium iodide (480mg, 1.13mmol, ⁇ 5eq) in THF ( 1 OmL) under Ar at room temperature). After stirring for 2hr with gradual warming to room temperature, the reaction mixture was cooled to 0°C and was quenched by the addition of 10% AcOH/THF (lOmL).
  • the immunosupressive activity was tested for deuterated cyclosporin analogs as described below. Compound 5e and compound 5g are more potent than the parent cyclosporin. Calcineurin activity was assayed using a modification of the method previously described by Fruman et al. (A Proc Natl Acad Sci USA, 1992). Whole blood lysates were evaluated for their ability to dephosphorylate a 32 P-labelled 19 amino acid peptide substrate in the presence of okadaic acid, a phosphatase type 1 and 2 inhibitor. Background phosphatase 2C activity (CsA and okadaic acid resistant activity) was determined and subtracted from each sample, with the assay performed in the presence and absence of excess added CsA.
  • the remaining phosphatase activity was taken as calcineurin activity.
  • the results of the calcineurin assay are presented in figure 5. The results are expressed as means ⁇ the standard error of the mean. The results are plotted as CsA derivative concentration in ug/L versus percentage of calcineurin inhibitation.
  • the structures of the compounds assayed include:
  • MLR mixed lymphocyte reaction
  • the MLR assay is useful for identifying CsA derivatives with biological (immunosuppressive) activity and to quantify this activity relative to the immunosuppressive activity of the parent CsA molecule.
  • lymphocyte proliferation assay procedure useful for this purpose is as follows:
  • the MLR assay can be utilized to select antibodies of the invention which bind biologically active
  • CSA metabolites and the parent CSA molecule.
  • Antibodies could also be selected for reactivity to biologically inactive metabolites.
  • cyclosporine derivatives of the invention which have been prepared include the following:
  • Drug Composition Formulation and Elicitation of Immunosupression Determination of the physicochemical, pharmacodynamic, toxicological and pharmacokinetic properties of the cyclosporine derivatives disclosed can be made using standard chemical and biological assays and through the use of mathematical modeling techniques which are known in the chemical and pharmacological/toxicological arts. The therapeutic utility and dosing regimen can be extrapolated from the results of such techniques and through the use of appropriate pharmacokinetic and/or pharmacodynamic models.
  • the compounds of this invention may be administered neat or with a pharmaceutical carrier to a warm blooded animal in need thereof.
  • the pharmaceutical carrier may be solid or liquid.
  • This invention also relates to a method of treatment for patients suffering from immunoregulatory abnormalities involving the administration of the disclosed cyclosporines as the active constituent.
  • a deuterated cyclosporin may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods.
  • the excipients used may be for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, or alginic acid; (3) binding agents such as starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874 to form osmotic therapeutic tablets for controlled release.
  • formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients may be
  • suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia;
  • dispersing or wetting agents which may be (a) a naturally-occurring phosphatide such as lecithin,
  • a condensation product of ethylene oxide with a long chain aliphatic alcohol for example, heptadecaethyleneoxycetanol
  • a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or
  • the aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose, aspartame or saccharin.
  • preservatives for example, ethyl or n-propyl p-hydroxybenzoate
  • coloring agents for example, ethyl or n-propyl p-hydroxybenzoate
  • flavoring agents for example, ethyl or n-propyl p-hydroxybenzoate
  • sweetening agents such as sucrose, aspartame or saccharin.
  • Oily suspension may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, those sweetening, flavoring and coloring agents described above may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil such as olive oil or arachis oils, or a mineral oil such as liquid paraffin or a mixture thereof.
  • Suitable emulsifying agents may be (1) naturally-occurring gums such as gum acacia and gum tragacanth, (2) naturally-occurring phosphatides such as soy bean and lecithin, (3) esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol, aspartame or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the disclosed cyclosporines may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • creams, ointments, jellies, solutions or suspensions, etc., containing the disclosed cyclosporines are employed.
  • Dosage levels of the order from about 0.05 mg to about 50 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (from about 2.5 mg to about 2.5 gms. per patient per day).
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration of humans may contain from 2.5 mg to 2.5 gm of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Dosage unit forms will generally contain between from about 5 mg to about 500 mg of active ingredient.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ces dérivés de cyclosporine sont dotés d'une efficacité renforcée et d'une toxicité réduite en comparaison des cyclosporines et des dérivés de cyclosporine d'origine naturelle présentement connus. On produit, dans le cadre de cette invention, les dérivés de cyclosporine par substitution chimique et isotopique de la molécule de cyclosporine A (CsA), (1), par substitution chimique et éventuellement substitution par du deutérium d'acide aminé 1 et, (2) par substitution par du deutérium à des sites clefs du métabolisme de la cyclosporine A, tels que les acides aminés 1, 4 et 9. Les dérivés les plus actifs sont ceux qui ont été substitués par voie chimique et par le deutérium. L'invention porte également sur des techniques de production de ces dérivés de cyclosporine ainsi que sur des méthodes de déclenchement d'immuno-suppression à toxicité réduite grâce à ces dérivés de cyclosporine.
PCT/IB1998/001693 1997-10-08 1998-10-08 Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs Ceased WO1999018120A1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
HK00105620.7A HK1026432B (en) 1997-10-08 1998-10-08 Deuterated and undeuterated cyclosporine analogs and their use as immunomodulating agents
BR9811716-5A BR9811716A (pt) 1997-10-08 1998-10-08 Análogos de ciclosporina deuterados e o seu emprego como agentes de modulação imunológica
CA002298572A CA2298572C (fr) 1997-10-08 1998-10-08 Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs
AT98947718T ATE314388T1 (de) 1997-10-08 1998-10-08 Deuterierte und undeuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agentien
NZ502362A NZ502362A (en) 1997-10-08 1998-10-08 Deuterated cyclosporine A derivatives and their use as immunomodulating agents
AU94542/98A AU750245B2 (en) 1997-10-08 1998-10-08 Deuterated cyclosporine analogs and their use as immunomodulating agents
KR1020007003743A KR100585348B1 (ko) 1997-10-08 1998-10-08 중수소화된 시클로스포린 유사체 및 면역조절제로서 그의용도
EP98947718A EP0991660B8 (fr) 1997-10-08 1998-10-08 ANALOGUES DE CYCLOSPORINE DEUTERES et non-deuteres ET LEUR UTILISATION COMME IMMUNOMODULATEURS
JP2000514928A JP4261049B2 (ja) 1997-10-08 1998-10-08 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用
DE69832984T DE69832984T2 (de) 1997-10-08 1998-10-08 DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
NO20001020A NO324042B1 (no) 1997-10-08 2000-02-29 Cyklosporin A derivat, farmasoytisk sammensetning innebefattende samme, anvendelse av samme for fremstilling av medikament og fremgangsmate for fremstilling av samme
US09/634,945 US6613739B1 (en) 1997-10-08 2000-08-07 Deuterated cyclosporine analogs and their use as immunomodulating agents
US09/639,708 US6605593B1 (en) 1997-10-08 2000-08-14 Deuterated cyclosporine analogs and their use as immunomodulating agents
AU27567/02A AU774744B2 (en) 1997-10-08 2002-03-21 Deuterated cyclosporine analogs and their use as immunomodulating agents
AU2004218637A AU2004218637B2 (en) 1997-10-08 2004-10-06 Deuterated cyclosporin analogs and their use as immunomodulating agents
US11/105,897 US7358229B2 (en) 1997-10-08 2005-04-13 Deuterated cyclosporin analogs and their use as immunomodulating agents
US11/245,775 US7538189B2 (en) 1997-10-08 2005-10-06 Methods of making deuterated cyclosporin analogs
US11/280,666 US7521421B2 (en) 1997-10-08 2005-11-15 Deuterated cyclosporine analogs and methods of making the same
US12/427,692 US20090318336A1 (en) 1997-10-08 2009-04-21 Deuterated Cyclosporine Analogs and Methods of Making the Same
US13/048,258 US20110166080A1 (en) 1997-10-08 2011-03-15 Deuterated cyclosporine analogs and methods of making the same
US13/402,370 US20120214745A1 (en) 1997-10-08 2012-02-22 Deuterated Cyclosporine Analogs and Methods of Making the Same
US14/182,231 US20140235819A1 (en) 1997-10-08 2014-02-17 Deuterated Cyclosporine Analogs and Methods of Making the Same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6136097P 1997-10-08 1997-10-08
US60/061,360 1997-10-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/048,258 Continuation US20110166080A1 (en) 1997-10-08 2011-03-15 Deuterated cyclosporine analogs and methods of making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18410998A Continuation 1997-10-08 1998-11-02

Publications (1)

Publication Number Publication Date
WO1999018120A1 true WO1999018120A1 (fr) 1999-04-15

Family

ID=22035297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001693 Ceased WO1999018120A1 (fr) 1997-10-08 1998-10-08 Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs

Country Status (14)

Country Link
US (3) US6613739B1 (fr)
EP (1) EP0991660B8 (fr)
JP (6) JP4261049B2 (fr)
KR (1) KR100585348B1 (fr)
AT (2) ATE314388T1 (fr)
AU (1) AU750245B2 (fr)
BR (1) BR9811716A (fr)
CA (1) CA2298572C (fr)
DE (2) DE69840586D1 (fr)
DK (1) DK0991660T3 (fr)
ES (1) ES2256959T3 (fr)
NO (1) NO324042B1 (fr)
NZ (1) NZ502362A (fr)
WO (1) WO1999018120A1 (fr)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033527A3 (fr) * 2001-10-19 2003-10-16 Isotechnika Inc Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs
WO2003033526A3 (fr) * 2001-10-19 2004-02-12 Isotechnika Inc Synthese d'analogues de cyclosporine
US6784156B2 (en) 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
WO2004089960A3 (fr) * 2003-04-08 2005-01-06 Isotechnika Inc Procede pour preparer un analogue de la cyclosporine a
US6979671B2 (en) 2001-10-12 2005-12-27 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
RU2317067C2 (ru) * 2001-10-19 2008-02-20 Изотехника Инк. Микроэмульсионный предконцентрат аналога циклоспорина
US7358229B2 (en) 1997-10-08 2008-04-15 Isotechnika Inc. Deuterated cyclosporin analogs and their use as immunomodulating agents
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
WO2012079172A1 (fr) 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367618B2 (en) 2009-01-30 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
DE102011111991A1 (de) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US9221878B2 (en) 2013-08-26 2015-12-29 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US9387230B2 (en) 2011-04-18 2016-07-12 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
USRE46629E1 (en) 2002-12-19 2017-12-12 Teva Pharmaceuticals International Gmbh Deuterated catecholamine derivatives and medicaments compromising said compounds
WO2018106928A1 (fr) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Traitement et prévention de maladies du vhb par des molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3
WO2020082061A1 (fr) 2018-10-19 2020-04-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de la voclosporine
US10918126B2 (en) 2006-03-08 2021-02-16 Retrotope, Inc. Isotopically modified compounds and their use as food supplements
EP4201952A1 (fr) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Procédé de synthèse contrôlée de voclosporine
EP4126905A4 (fr) * 2020-03-26 2024-05-29 Farsight Medical Technology (Shanghai) Co., Ltd. Inhibiteurs de cyclophiline et leurs utilisations
IT202300001116A1 (it) * 2023-01-25 2024-07-25 Indena Spa Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
US12077604B2 (en) 2018-01-12 2024-09-03 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
DE60042425D1 (de) 1999-04-30 2009-07-30 Univ Michigan Verwendung von Benzodiazepinen zur Behandlung von autoimmunischen Krankheiten, Entzündungen, Neoplasien, viralen Infektionen und Atherosklerosis
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20040110666A1 (en) * 2002-12-04 2004-06-10 Or Yat Sun Cyclosporins for the treatment of immune disorders
US20040266669A1 (en) * 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2005094897A2 (fr) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Derives de composes de modulation des canaux ioniques, compositions pharmaceutiques et utilisations
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
AU2005326322B2 (en) * 2004-07-01 2009-02-05 Yale University Targeted and high density drug loaded polymeric materials
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
CA2575280C (fr) * 2004-07-29 2012-08-14 Amr Technology, Inc. Nouveaux procedes de synthese stereoselective d'un compose isa<sb>tx</sb>247 trans
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
CA2586925C (fr) 2004-11-18 2016-06-07 Cardiome Pharma Corp. Processus de preparation par synthese de composes d'aminocyclohexyle ether
CA2592343A1 (fr) * 2004-12-17 2006-06-22 Isotechnika Inc. Metabolites d'analogues de la cyclosporine
WO2006074358A1 (fr) * 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions et procedes concernant de nouveaux composes et leurs cibles
DE602006012033D1 (de) * 2005-04-06 2010-03-18 Abbott Lab Verfahren zur messung immunsuppressiver tacrolimus-, sirolimus- und cyclosporin-a-komplexe in einer blutprobe
AU2006309291B2 (en) 2005-06-01 2010-05-27 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
JP5159616B2 (ja) 2005-06-15 2013-03-06 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物の調製のための合成プロセス
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
EP2604269B1 (fr) 2005-11-01 2014-09-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones possédant des propriétés thérapeutiques
CA2628570A1 (fr) 2005-11-09 2007-05-18 Combinatorx, Incorporated Procedes, compositions et kits pour le traitement de pathologies
DK1954669T3 (en) 2005-12-01 2015-10-12 Auspex Pharmaceuticals Inc SUBSTITUTED phenethylamines a serotonergic AND / OR NOREPINEPHRINERG ACTIVITY
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US8155649B2 (en) * 2006-05-12 2012-04-10 Shared Spectrum Company Method and system for classifying communication signals in a dynamic spectrum access system
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
US20100151436A1 (en) * 2007-03-02 2010-06-17 Fong Peter M Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
NZ579507A (en) * 2007-03-09 2011-11-25 Univ Michigan Compositions and methods relating to novel compounds and targets thereof
ES2716048T3 (es) 2007-03-15 2019-06-07 Auspex Pharmaceuticals Inc Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
US20100297666A1 (en) * 2007-08-01 2010-11-25 Gooch Jennifer L Methods for determination of protein phosphatase activity, and uses in predicting therapeutic outcomes
EP2200977B1 (fr) 2007-09-14 2016-11-09 The Regents of the University of Michigan Inhibiteur de f1f0-atpase et procédés associés
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
CA2715036A1 (fr) 2008-03-14 2009-09-17 Retrotope, Inc. Therapies contre le cancer utilisant de la lysine substituee isotopiquement
BRPI0916769A2 (pt) * 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
CN102164948A (zh) * 2008-07-30 2011-08-24 伊索技术制药公司 非免疫抑制的环孢菌素类似分子
WO2010027448A1 (fr) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals Inc. Dérivés d'acide pyrimidin-5-ylacétique enrichis en isotopes en tant qu'antagonistes de crth2
CA2736091A1 (fr) * 2008-09-03 2010-03-11 Teva Pharmaceutical Industries Ltd. Modulateurs 2-oxo-1,2-dihydro-quinoleines de la fonction immunitaire
EP2352724B1 (fr) 2008-09-11 2015-04-22 The Regents of the University of Michigan Aryle guanidines comme inhibiteurs de la f1f0-atpase et leur utilisation medicale
BRPI0919920A2 (pt) * 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
WO2011035124A1 (fr) 2009-09-18 2011-03-24 The Regents Of The University Of Michigan Composés de benzodiazépinone et méthodes de traitement les utilisant
EP2493296B1 (fr) 2009-10-30 2019-01-09 Retrotope, Inc. Soulagement de troubles liés au stress oxydatif par des dérivés de pufa
CA2780287C (fr) 2009-11-17 2015-03-17 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones et composes apparentes presentant des proprietes therapeutiques
AU2010322286B2 (en) 2009-11-17 2014-06-05 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
EP3730135A1 (fr) 2011-04-26 2020-10-28 Retrotope, Inc. Troubles de traitement compromis de l'énergie et déficiences mitochondriales
WO2012148930A2 (fr) 2011-04-26 2012-11-01 Retrotope, Inc. Rétinopathies oxydatives
KR102110175B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
WO2013074650A1 (fr) 2011-11-18 2013-05-23 Codexis, Inc. Biocatalyseurs pour la préparation de carbamates hydroxy substitués
EP2841098A4 (fr) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanoparticules pour le traitement d'allergies
EP3760223A1 (fr) 2013-04-03 2021-01-06 N-Fold Llc Nouvelles compositions de nanoparticules
EP3094314B1 (fr) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Nanosupports ciblés pour l'administration d'agents immunosuppresseurs
US10730821B2 (en) 2015-11-23 2020-08-04 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
JP2023514711A (ja) 2020-02-21 2023-04-07 レトロトップ、 インコーポレイテッド 多価不飽和脂肪酸及びその誘導体の同位体修飾方法
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2025119925A1 (fr) 2023-12-05 2025-06-12 Medichem, S.A. Procédé de préparation de voclosporine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283801A2 (fr) * 1987-03-27 1988-09-28 Abbott Laboratories Essais de polarisation par fluorescence pour cyclosporine A et les métabolites et immunogènes et anticorps apparentés
EP0373260A1 (fr) * 1987-06-22 1990-06-20 Merck & Co. Inc. Dérivés de cyclosporine avec un acide aminé modifié en position 8
EP0577544A1 (fr) * 1992-03-02 1994-01-05 Sandoz Ltd. Nouvelles cyclosporines modifiées en position 1
WO1995026325A2 (fr) * 1994-03-25 1995-10-05 Isotechnika Inc. Potentialisation de medicaments par deuteration_______________

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210581A (en) 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (fr) 1975-11-04 1979-12-28 Sandoz Ag
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DE2819094A1 (de) 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en) 1979-03-12 1980-05-06 Merck & Co., Inc. Antibiotic A43F
EP0098457B1 (fr) 1980-02-14 1987-08-05 Sandoz Ag (1S,2R,3R)-et (1R,2S,3S)-Nitrilo-1-carbonyl-3-méthyl-2-oxy-heptanes et-hept-5-ènes utiles dans la synthèse totale de cyclosporines et procédé pour leur préparation
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
FR2487198A1 (fr) 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
US4384996A (en) 1981-01-09 1983-05-24 Sandoz Ltd. Novel cyclosporins
CH667274A5 (de) 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4727018A (en) 1984-05-18 1988-02-23 Eichner Ronald D Immunoregulation of transplantable tissue
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8422253D0 (en) 1984-09-04 1984-10-10 Sandoz Ltd Organic compounds
EP0194972B1 (fr) 1985-03-11 1992-07-29 Sandoz Ag Cyclosporines
US4765980A (en) 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4764503A (en) 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
NL194638C (nl) 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
US5427960A (en) 1987-03-27 1995-06-27 Abbott Laboratories Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
US5239057A (en) 1987-03-27 1993-08-24 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ES2059558T3 (es) * 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
EP0296123B1 (fr) 1987-06-19 1994-08-31 Sandoz Ag Peptolides cycliques
GB8717300D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
GB8717299D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Peptides
US5227467A (en) 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
WO1989001772A1 (fr) 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Composition de cyclosporine oculaire
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5089390A (en) 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US4914188A (en) 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5236899A (en) 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US5013719A (en) 1988-05-13 1991-05-07 Merrell Dow Pharmaceuticals Inc. Method of effecting immunosuppression
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
WO1990006763A1 (fr) 1988-12-05 1990-06-28 The Trustees Of Columbia University In The City Of New York Nouveaux derives de cyclosporine a, leurs anticorps et leurs utilisations
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5214130A (en) 1990-02-27 1993-05-25 Merck & Co., Inc. Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
DK0473961T3 (da) 1990-08-15 1996-07-01 Abbott Lab Immunoassay-reagenser og fremgangsmåde til bestemmelse af cyklosporin
DE69124459T3 (de) 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
US5115859A (en) 1990-12-21 1992-05-26 United Technologies Corporation Regenerable non-venting cooler for protective suit
ATE127528T1 (de) 1991-04-06 1995-09-15 Dresden Arzneimittel Verfahren zur fermentativen herstellung und isolierung von cyclosporin a sowie neue cyclosporin- bildende stämme.
HU213553B (en) 1992-05-25 1997-07-28 Biogal Gyogyszergyar Process for isolating of cyclosporin-a
FI92334C (fi) 1992-12-30 1994-10-25 Leiras Oy Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
CA2161149A1 (fr) 1993-05-04 1994-11-10 James M. Balkovec Ether-oxydes de cyclohexapeptidyle et d'aminoalkyle
US5639852A (en) 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US5747330A (en) 1996-06-05 1998-05-05 Poli Industria Chimica Antibiotic producing microbe
US5709797A (en) 1996-06-05 1998-01-20 Poli Industria Chimica S.P.A. Method of isolating cyclosporins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283801A2 (fr) * 1987-03-27 1988-09-28 Abbott Laboratories Essais de polarisation par fluorescence pour cyclosporine A et les métabolites et immunogènes et anticorps apparentés
EP0373260A1 (fr) * 1987-06-22 1990-06-20 Merck & Co. Inc. Dérivés de cyclosporine avec un acide aminé modifié en position 8
EP0577544A1 (fr) * 1992-03-02 1994-01-05 Sandoz Ltd. Nouvelles cyclosporines modifiées en position 1
WO1995026325A2 (fr) * 1994-03-25 1995-10-05 Isotechnika Inc. Potentialisation de medicaments par deuteration_______________

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. SEEBACH ET AL.: "MODIFICATION OF CYCLOSPORIN A (CS): GENERATION OF AN ENOLATE AT THESARCOSINE RESIDUE AND REACTIONS WITH ELECTROPHILES", HELVETICA CHIMICA ACTA, vol. 76, 1993, pages 1564 - 1590, XP002022424 *
EBERLE M K ET AL: "Modifications of the MeBmt Side Chain of Cyclosporin A", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 15, 3 August 1995 (1995-08-03), pages 1725-1728, XP004135415 *
H. KOBEL ET AL.: "Contribution to knowledge of the biosynthesis of cyclosporin A", EXPERIENTIA, vol. 39, 1983, pages 873 - 876, XP002090783 *

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538189B2 (en) 1997-10-08 2009-05-26 Isotechnika Inc. Methods of making deuterated cyclosporin analogs
US7521421B2 (en) 1997-10-08 2009-04-21 Isotechnika Inc. Deuterated cyclosporine analogs and methods of making the same
US7358229B2 (en) 1997-10-08 2008-04-15 Isotechnika Inc. Deuterated cyclosporin analogs and their use as immunomodulating agents
US7012064B2 (en) 2001-03-05 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
US6784156B2 (en) 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
US6979671B2 (en) 2001-10-12 2005-12-27 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
JP2011006417A (ja) * 2001-10-19 2011-01-13 Isotechnika Inc シクロスポリン類似体混合物及びそれらの免疫調整剤としての使用
US20110092669A1 (en) * 2001-10-19 2011-04-21 Isotechnika Inc. Synthesis of cyclosporin analogs
JP2013136597A (ja) * 2001-10-19 2013-07-11 Isotechnika Pharma Inc シクロスポリン類似体混合物及びそれらの免疫調整剤としての使用
EP1714977A2 (fr) 2001-10-19 2006-10-25 Isotechnika Inc. Synthèse d'analogues de cyclosporine
US7141648B2 (en) 2001-10-19 2006-11-28 Isotechnika Inc. Synthesis of cyclosporin analogs
EP1714977A3 (fr) * 2001-10-19 2007-01-10 Isotechnika Inc. Synthèse d'analogues de cyclosporine
EP1816138A1 (fr) * 2001-10-19 2007-08-08 Isotechnika,Inc. Mélanges analogues de cyclosporine et leur utilisation en tant qu'agents immunomodulateurs
CN100334106C (zh) * 2001-10-19 2007-08-29 伊索泰克尼卡股份有限公司 环孢菌素类似物的合成
CN100344648C (zh) * 2001-10-19 2007-10-24 伊索泰克尼卡股份有限公司 环孢菌素类似物混合物及其在制备免疫调节剂中的用途
US7332472B2 (en) 2001-10-19 2008-02-19 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
RU2317067C2 (ru) * 2001-10-19 2008-02-20 Изотехника Инк. Микроэмульсионный предконцентрат аналога циклоспорина
RU2321593C2 (ru) * 2001-10-19 2008-04-10 Изотехника Инк. Синтез аналогов циклоспорина
JP2005511538A (ja) * 2001-10-19 2005-04-28 アイソテクニカ インコーポレーテッド シクロスポリン類似体混合物及びそれらの免疫調節剤としての使用
US20140288266A1 (en) * 2001-10-19 2014-09-25 Aurinia Pharmaceuticals, Inc. Synthesis of Cyclosporin Analogs
US9765119B2 (en) 2001-10-19 2017-09-19 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
RU2321593C9 (ru) * 2001-10-19 2008-06-20 Изотехника Инк. Синтез аналогов циклоспорина
RU2337106C2 (ru) * 2001-10-19 2008-10-27 Изотехника Инк. Смесь аналогов циклоспорина и ее применение в качестве иммуномодулирующего агента
JP2009046515A (ja) * 2001-10-19 2009-03-05 Isotechnika Inc シクロスポリン類似体の合成法
US10472394B2 (en) 2001-10-19 2019-11-12 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
HRP20040355B1 (hr) * 2001-10-19 2012-10-31 Isotechnika Inc. Sinteza ciklosporinskih analoga
WO2003033526A3 (fr) * 2001-10-19 2004-02-12 Isotechnika Inc Synthese d'analogues de cyclosporine
USRE48226E1 (en) 2001-10-19 2020-09-29 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
JP2009197036A (ja) * 2001-10-19 2009-09-03 Isotechnika Inc シクロスポリン類似体混合物及びそれらの免疫調節剤としての使用
HRP20040353B1 (hr) * 2001-10-19 2012-10-31 Isotechnika Inc. Smjese analoga ciklosporina i njihova uporaba kao imunomodulirajuä†ih sredstava
US6998385B2 (en) 2001-10-19 2006-02-14 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
KR100992850B1 (ko) * 2001-10-19 2010-11-09 이소테크니카 인코포레이티드 시클로스포린 유사체 혼합물 및 면역조절제로서 이들의 용도
JP2010280710A (ja) * 2001-10-19 2010-12-16 Isotechnika Inc シクロスポリン類似体の合成法
WO2003033527A3 (fr) * 2001-10-19 2003-10-16 Isotechnika Inc Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs
HRP20070058B1 (hr) * 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
USRE46629E1 (en) 2002-12-19 2017-12-12 Teva Pharmaceuticals International Gmbh Deuterated catecholamine derivatives and medicaments compromising said compounds
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
WO2004089960A3 (fr) * 2003-04-08 2005-01-06 Isotechnika Inc Procede pour preparer un analogue de la cyclosporine a
EP1804823A4 (fr) * 2004-09-29 2010-06-09 Amr Technology Inc Nouveaux analogues de la cyclosporine et leurs utilisations pharmaceutiques
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7632807B2 (en) 2004-10-06 2009-12-15 Albany Molecular Research, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US10918126B2 (en) 2006-03-08 2021-02-16 Retrotope, Inc. Isotopically modified compounds and their use as food supplements
US8367618B2 (en) 2009-01-30 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
EP3461835A1 (fr) 2010-12-15 2019-04-03 ContraVir Pharmaceuticals, Inc. Molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3
WO2012079172A1 (fr) 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3
US9714271B2 (en) 2010-12-15 2017-07-25 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
US9387230B2 (en) 2011-04-18 2016-07-12 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
US9453051B2 (en) 2011-08-30 2016-09-27 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Cyclosporin derivatives
WO2013030208A1 (fr) 2011-08-30 2013-03-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Dérivés de cyclosporine
DE102011111991A1 (de) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US9221878B2 (en) 2013-08-26 2015-12-29 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2018106928A1 (fr) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Traitement et prévention de maladies du vhb par des molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3
US12077604B2 (en) 2018-01-12 2024-09-03 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
WO2020082061A1 (fr) 2018-10-19 2020-04-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de la voclosporine
EP4126905A4 (fr) * 2020-03-26 2024-05-29 Farsight Medical Technology (Shanghai) Co., Ltd. Inhibiteurs de cyclophiline et leurs utilisations
EP4126904A4 (fr) * 2020-03-26 2024-05-29 Farsight Medical Technology (Shanghai) Co., Ltd. Préparation de dérivés de cyclosporine
EP4201952A1 (fr) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Procédé de synthèse contrôlée de voclosporine
WO2023118045A1 (fr) 2021-12-21 2023-06-29 Curia Spain, S.A.U. Procédé de synthèse contrôlée de la voclosporine
IT202300001116A1 (it) * 2023-01-25 2024-07-25 Indena Spa Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
WO2024157132A1 (fr) * 2023-01-25 2024-08-02 Indena S.P.A. Procédé de préparation d'un intermédiaire utile pour la synthèse de la voclosporine

Also Published As

Publication number Publication date
US6605593B1 (en) 2003-08-12
DK0991660T3 (da) 2006-02-13
JP2007119489A (ja) 2007-05-17
HK1026432A1 (en) 2000-12-15
NO20001020D0 (no) 2000-02-29
AU750245B2 (en) 2002-07-11
CA2298572C (fr) 2002-04-09
DE69832984T2 (de) 2006-09-21
EP0991660A1 (fr) 2000-04-12
NO324042B1 (no) 2007-07-30
US20020132763A1 (en) 2002-09-19
ATE423130T1 (de) 2009-03-15
KR20010030978A (ko) 2001-04-16
JP2008222724A (ja) 2008-09-25
ATE314388T1 (de) 2006-01-15
JP2005343904A (ja) 2005-12-15
JP2001519355A (ja) 2001-10-23
EP0991660B8 (fr) 2006-04-05
US6613739B1 (en) 2003-09-02
DE69840586D1 (de) 2009-04-02
DE69832984D1 (de) 2006-02-02
ES2256959T3 (es) 2006-07-16
BR9811716A (pt) 2000-07-18
NO20001020L (no) 2000-02-29
AU9454298A (en) 1999-04-27
JP4261049B2 (ja) 2009-04-30
KR100585348B1 (ko) 2006-06-01
JP2004143168A (ja) 2004-05-20
NZ502362A (en) 2001-05-25
CA2298572A1 (fr) 1999-04-15
JP2008222725A (ja) 2008-09-25
EP0991660B1 (fr) 2005-12-28

Similar Documents

Publication Publication Date Title
EP0991660B1 (fr) ANALOGUES DE CYCLOSPORINE DEUTERES et non-deuteres ET LEUR UTILISATION COMME IMMUNOMODULATEURS
US7521421B2 (en) Deuterated cyclosporine analogs and methods of making the same
US5227467A (en) Immunosuppressive fluorinated cyclosporin analogs
GB2212499A (en) Cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
CA2036963A1 (fr) Anologues immunosuppressuers de la cyclosporine presentant des acides amines modifies en position 8
Papageorgiou et al. Improved binding affinity for cyclophilin A by a cyclosporin derivative singly modified at its effector domain
GB2207678A (en) Novel immunosuppressive fluorinated cyclosporin analogs
EP1645565B1 (fr) Analogue de la cyclosporine deuterié et luers utilisations comme agents immunomodulés
CA2511888C (fr) Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs
AU774744B2 (en) Deuterated cyclosporine analogs and their use as immunomodulating agents
AU2004218637B2 (en) Deuterated cyclosporin analogs and their use as immunomodulating agents
HK1026432B (en) Deuterated and undeuterated cyclosporine analogs and their use as immunomodulating agents
MXPA00002068A (en) Deuterated cyclosporine analogs and their use as immunomodulating agents
CA2372639C (fr) Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 502362

Country of ref document: NZ

Ref document number: 94542/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2298572

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1998947718

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/002068

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020007003743

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1998947718

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007003743

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 94542/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998947718

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020007003743

Country of ref document: KR